Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Study Evaluating the Safety, Pharmacology, and Clinical Effect of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

NCT06181266 is registered in ClinicalTrials.gov with Prokarium Ltd as lead sponsor.

NCT NCT06181266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06181266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Study Evaluating the Safety, Pharmacology, and Clinical Effect of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer
Lead sponsor
Prokarium Ltd
Phase
Phase 1
Overall status
Completed
Start date
January 8, 2024
Completion date
August 5, 2026
Enrollment
22 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

high risk nmibc, nmibc, non muscle invasive bladder cancer